Adapt Immune

Cell & Gene Therapy · Health Care

Facts

as of Nov 17, 2026

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients.

Legal name
Adaptimmune Limited
Employees
501-1000estimated range
Register numbers
CRN 06456741 · VAT GB207918693000
Official records
Companies House 06456741
Website
adaptimmune.com
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Legal entity active
Adaptimmune Limited
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Financials

Funding rounds, investors and revenue on record.

Venture - Series UnknownLatest round
10Rounds and grants
Money by yearUSD, rounds and grants
2014-2 records
2013-1 record
2012-3 records
2011-2 records
2010-2 records
Sources: funding announcements, grant and company registers

Milestones

Aug 23, 2014
Raised a round Venture round
Apr 7, 2014
Raised a round Venture round
Each milestone is dated by its source: registers, filings, the press

Newsroom

Nov 17, 20252025
Press release
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") toda…
Oct 20, 20252025
Press release
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today an…
Aug 13, 20252025
Press release
Q2 Tecelra sales of $11.1m with 16 patients invoiced represents 150% growth vs Q1 2025 Entered into a definitive agreement for the sale of TECELRA, lete-cel, afami-cel, and uza-c…
Jul 28, 20252025
News · YahooFinance
A deal with US WorldMeds includes the FDA-approved TCR therapy Tecelra and two clinical-stage cancer medicines.
Jul 28, 20252025
Press release
Tecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration wi…
May 13, 20252025
Press release
TECELRA launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced $4.0 million Tecelra net sales in Q1 2025 Instituting 2025 Tecelra full year sales…
Sources: the outlets named on each headline, each story once